Quantum X Labs Q3: Revenue Falls to $900K, Operating Loss Widens to $3.99M, Going Concern Reaffirmed
QXL has more than doubled off its 52-week low of $0.961 on light trading volume (0.4× avg).
Summary
Quantum X Labs' Q3 10-Q shows nine-month revenue down to $900K, operating loss widened to $3.99M, and a reaffirmed going-concern warning, with the share count roughly doubled to 21.87M on warrant exercises and acquisition stock.
Key Events · Earnings and Guidance · QXL
-
Revenue Shrinks, Losses Widen
Nine-month revenue fell to $900 thousand from $1,300 thousand, and the operating loss widened to $3,993 thousand from $1,603 thousand a year earlier.
-
Going Concern Doubt Reaffirmed
Management states substantial doubt about the ability to continue as a going concern for 12 months after issuance, with $2,373 thousand of cash against a $50,046 thousand accumulated deficit.
-
Share Count Nearly Doubles
Shares outstanding rose to 21,867,826 from 10,670,392 at December 31, 2025, driven by 7,887,987 warrant exercises and 1,866,000 shares issued for the Quantum Israel acquisition.
-
Quantum Israel Earn-Out Hangs Over Stock
The March 4, 2026 acquisition cost $15,171 thousand in total consideration and carries up to 12,702,847 additional shares or pre-funded warrants tied to patent, listing and $250 million valuation milestones.
Analysis · QXL · Technology
The core problem showed no relief this quarter: the legacy search-advertising business keeps shrinking while the newly acquired quantum research unit burns cash without revenue. Nine-month revenue fell to $900 thousand from $1.3 million, and the operating loss more than doubled to $3.99 million from $1.6 million, with Quantum Israel alone contributing a $1.11 million operating loss. Management again states substantial doubt about continuing as a going concern over the next 12 months, and the balance sheet shows why: $2.37 million of cash against a $50.05 million accumulated deficit. The company is staying alive on warrant exercises ($4.28 million from June to October 2026) and small private placements, which is why the share count roughly doubled to 21.87 million from 10.67 million at year-end 2025. The offsetting asset is the Quantum Israel deal — $15.17 million of consideration, mostly stock and pre-funded warrants, plus up to 12.7 million earn-out shares tied to patent, listing and $250 million valuation milestones. Those milestones are the only visible path to value, and they sit alongside a shareholder base that has already absorbed heavy dilution.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QXL was trading at $3.21 on NASDAQ in the Technology sector, with a market capitalization of approximately $69.2M. The 52-week trading range was $0.96 to $7.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.